Liminatus Pharma Inc. LIMN
4.20
0.02
0.48%
as of 25 Sep
- Market cap
- $5.6M
- P/E
- 0.0×
Follow LIMN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.12 | 0.96 | 0.05 | 0.42 |
+6 more quarters Free account |
Net Debt/EBITDA |
1.14 | 0.42 | (1.25) | (1.02) | |
Debt/Assets |
42.38% | 51.70% | 281.30% | 107.46% | |
Debt/Equity |
4.80 | (10.88) | (0.15) | (0.88) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 1.79 | 0.05 | 0.33 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (21.83) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.00) | (2.80) | (0.81) | (1.14) | |
Cash per Share |
3.12 | 2.65 | 0.71 | 1.34 | |
Shareholders Equity per Share |
0.31 | (0.18) | (20.66) | (3.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.31 | (0.18) | (20.66) | (3.05) | |
Free Cash Flow |
(0.97) | (2.02) | (0.39) | (0.61) | |
Working Capital |
0.35 | (0.11) | (9.80) | (1.66) | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
0.29 | (0.14) | (9.83) | (1.78) | |
| Other line items | |||||
Quick Ratio |
0.99 | 0.66 | 0.03 | 0.25 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.00) | (2.80) | (0.81) | (1.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Average Payables |
0.54 | 1.01 | — | — | |
Average Assets |
2.66 | 1.40 | 2.96 | 0.67 | |
Average Common Equity |
(4.25) | (0.07) | (14.58) | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates